| Description | IRAK4-IN-7 (CA-4948) is a selective and potent IRAK4 kinase inhibitor with in vivo activity in a TLR4-induced cytokine release model. |
| In vitro | CA-4948 was previously shown to exhibit dose-dependent efficacy in ABC-DLBCL MYD88-L265P xenograft tumor models using cell lines OCI-LY3 and OCI-LY10[1]. |
| In vivo | CA-4948 has antitumor activity in ABC-type diffuse large B cell lymphoma patient-derived xenograft (PDX) mouse models[2]. |
| Synonyms | CA-4948 |
| molecular weight | 417.42 |
| Molecular formula | C21H19N7O3 |
| CAS | 1801343-74-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 13.89 mg/mL (33.28 mM) |
| References | 1. Robert N. Booher, et al. Abstract 1168: Efficacy of the IRAK4 inhibitor CA-4948 in patient-derived xenograft models of diffuse large B cell lymphoma. AACR Annual Meeting 2017; April 1-5, 2017; 2. Booher, R.N., Samson, M.E., Xu, G.-X., et al. Abstract 1168: Efficacy of the IRAK4 inhibitor CA-4948 in patient-derived xenograft models of diffuse large B cell lymphoma. Cancer Res. 77(13 Supp), 1168 (2017). |